SHANGHAI – Making a strong move to enter China's cardiovascular (CDV) market, Shanghai-based Eddingpharm Co. Ltd. inked a deal with Amarin Corp. plc, of Dublin, to bring Vascepa to Greater China. Amarin will receive a nonrefundable $15 million up-front payment, while the total deal is valued at $169 million in milestones and tiered sales royalties.
SHANGHAI – Making a strong move to enter China's cardiovascular (CDV) market, Shanghai-based Eddingpharm Co. Ltd. inked a deal with Amarin Corp. plc, of Dublin, to bring Vascepa to Greater China.
SHANGHAI – The evolving story of CASI Pharmaceuticals Inc. is about a Nasadaq-listed firm hoping for a fresh start as a China-focused oncology company without letting go of its American roots.
SHANGHAI – China has seen a massive rise in patent filings over the last seven years, with the number of published patents growing an average of 16 percent annually.
SHANGHAI – The five month old GPCR Consortium – which brings together industry and academics to explore the G protein-coupled receptors (GPCRs) family of proteins – has added two new pharmaceutical members to its fold. It now counts Novo Nordisk AS and Merck & Co. Inc. as members in addition to founding members Amgen Inc., Ono Pharmaceutical Co. Ltd. and Sanofi SA. The partners provide not just funding to the research consortium's efforts.
SHANGHAI – China has seen a massive rise in patent filings over the last seven years, with the number of published patents growing an average of 16 percent annually. (See story this issue.)
SHANGHAI – The five month old GPCR Consortium – which brings together industry and academics to explore the G protein-coupled receptors (GPCRs) family of proteins – has added two new pharmaceutical members to its fold. It now counts Novo Nordisk AS and Merck & Co. Inc. as members in addition to founding members Amgen Inc., Ono Pharmaceutical Co. Ltd. and Sanofi SA.
SHANGHAI – Hua Medicine Ltd.'s sinogliatin, a fourth-generation glucokinase activator (GKA), looks set to prove it has overcome the issues of past GKAs to provide 24-hour glucose control in diabetics with the potential to improve pancreatic beta cell function.
SHANGHAI – Hua Medicine Ltd.'s sinogliatin, a fourth-generation glucokinase activator (GKA), looks set to prove it has overcome the issues of past GKA's to provide 24-hour glucose control in diabetics with the potential to improve pancreatic beta cell function.
SHANGHAI – Glaxosmithkline plc, of London, has firmly denied rumors of sizable layoffs in its troubled China operation, reasserting its commitment to the country. While the company is sticking to its story that nobody will be let go, the firm also said in a statement it will continue to "realign resources to build a highly efficient and sustainable business."
